News Search Results
Dec 11, 2025, 18:09 ET FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Dec 11, 2025, 18:02 ET Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the presentation of final data from the Phase 1 clinical trial of its
More news about: Anixa Biosciences, Inc.
Dec 11, 2025, 16:40 ET InstaMed® Pharmaceuticals Announces Month-Over-Month Hypergrowth, Successful Study, and Expands Its Patented Peptide Delivery Platform Nationwide
SALT LAKE CITY, Dec. 11, 2025 /PRNewswire/ -- InstaMed® Pharmaceuticals, a biotechnology innovator, is pioneering the first patented non-injectable peptide delivery system, InstaRelease®, a breakthrough oral dissolving
More news about: InstaMed® Pharmaceuticals
Dec 11, 2025, 16:04 ET FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
progress.-ENDS- About Neurizon Therapeutics LimitedNeurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment
More news about: Neurizon Therapeutics Limited
Dec 11, 2025, 15:49 ET FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
-ENDS- About Neurizon Therapeutics LimitedNeurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment
More news about: Neurizon Therapeutics Limited
Dec 11, 2025, 13:22 ET Wobble Genomics To Present New Data At SABCS Confirming Platform's Ability To Determine Detailed Profiling of HER2 Status in Tissue and Blood
EDINBURGH, Scotland, Dec. 11, 2025 /PRNewswire/ -- Wobble Genomics, a biotechnology company focused on improving cancer outcomes through better diagnosis and therapy selection, will present new data at the 2025 San Antonio Breast
More news about: Wobble Genomics
Dec 11, 2025, 10:30 ET Rapafusyn Founder Dr. Jun O. Liu Elected as National Academy of Inventors Fellow
healthBALTIMORE, Dec. 11, 2025 /PRNewswire/ -- Rapafusyn Pharmaceuticals, a biotechnology company advancing next-generation molecular glue therapeutics for hard-to-drug targets, today announced that its founder, Dr. Jun O. Liu of the
More news about: Rapafusyn Pharmaceuticals
Dec 11, 2025, 10:15 ET Cell Therapy Technologies Market worth $7.91 billion by 2030 | MarketsandMarkets™
biopharmaceutical & biotechnology companies' segment is estimated to register the highest CAGR from 2025 to 2030the market has been classified into biopharmaceutical & biotechnology companies, CROS & CMOs, research institutes, and cell banks. Biopharmaceutical and biotechnology companies accounted
More news about: MarketsandMarkets
Dec 11, 2025, 09:03 ET Sōlaria Biō Announces Breakthrough Study Demonstrating Connection Between Gut Barrier, Inflammation and Bone Health
Sōlaria Biō, a biotechnology company pioneering natural solutions for healthy aging, announced new mechanistic research that unlocks how the gut–bone axis can be leveraged to
More news about: Sōlaria Biō
Dec 11, 2025, 08:32 ET Gerosynth Labs Announces Investigational New Animal Drug (INAD) Acceptances Spanning Equine, Feline, and Canine Oncology
BLOOMINGTON, Minn., Dec. 11, 2025 /PRNewswire/ -- Gerosynth Labs, Inc., a private biotechnology company pioneering novel oncology and cellular-health therapeutics, today announced that the U.S. Food and Drug Administration Center for Veterinary
More news about: Gerosynth Labs, Inc.
Dec 11, 2025, 08:32 ET Sen-Jam Pharmaceutical Secures Major Strategic Partnership with TASK Clinical to Fund Two-Thirds of Phase 3 Trial for SJP-001
HUNTINGTON, N.Y., Dec. 11, 2025 /PRNewswire/ -- Sen-Jam Pharmaceutical, a clinical-stage biotechnology company pioneering novel anti-inflammatory combination therapeutics, today announced a transformative partnership with TASK Clinical, a global contract
More news about: Sen-Jam Pharmaceutical
Dec 11, 2025, 08:00 ET HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
SAN FRANCISCO, Dec. 11, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that new clinical data from its flagship
More news about: HanchorBio Inc.
Dec 11, 2025, 07:47 ET Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
Dec. 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates
More news about: Intensity Therapeutics Inc.
Dec 11, 2025, 07:30 ET Brii Biosciences and OpenBench Announce AI-Driven Collaboration for Proprietary Technology Platform
Dec. 11, 2025 /PRNewswire/ -- OpenBench, Inc., a biotechnology company pioneering success-driven molecular discovery partnerships, and Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with
More news about: OpenBench; Brii Biosciences
Dec 11, 2025, 07:00 ET NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a next-generation biotechnology company developing advanced cell-therapy and neuroscience-driven therapeutics, today announced the publication of a major international patent application
More news about: NewcelX Ltd.
Dec 11, 2025, 06:45 ET Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Dec 11, 2025, 03:03 ET India's Future Innovators to Converge at BML Munjal University for Heroes of Tomorrow Finale
cities including Hyderabad, Ludhiana, Dehradun and Delhi attracted strong participation, with students presenting business ideas in clean energy, biotechnology, healthcare technology, biodegradable materials and smart consumer solutions.The Hyderabad round, hosted at Canary The School, brought together
More news about: BML Munjal University
Dec 11, 2025, 01:00 ET OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases
Dec. 11, 2025 /PRNewswire/ -- OTR Therapeutics, a biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies for unmet medical needs, and Zealand Pharma A/S (Nasdaq: ZEAL), a biotechnology company transforming the future of metabolic health, today
More news about: OTR Therapeutics
Dec 10, 2025, 12:34 ET Locus FS Secures $40 Million in Strategic Investment to Accelerate Biomanufacturing & Bio-Based Additive Growth
Locus Fermentation Solutions (Locus FS), a U.S.-based biotechnology company producing performance-enhancing bio-based additives, today announced the close of an oversubscribed $20 million investment in a convertible
More news about: Locus Fermentation Solutions
Dec 10, 2025, 09:00 ET Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, will participate in the upcoming
More news about: Anixa Biosciences, Inc.
Dec 10, 2025, 09:00 ET Siolta Therapeutics Announces Upcoming Late Breaking Oral Presentation of Results from the Phase 2 ADORED trial at 2026 AAAAI meeting
SAN CARLOS, Calif., Dec. 10, 2025 /PRNewswire/ -- Siolta Therapeutics, a biotechnology company developing first-in-class live biotherapeutic products (LBPs), today announced that its abstract describing the one year results from the
More news about: Siolta Therapeutics
Dec 10, 2025, 09:00 ET Transformative Biotech Appoints Industry Veteran Kevin Kraus as CEO
board as we move our company forward and drive commercialization." About Transformative BiotechTransformative Biotech is a biotechnology company focused on deploying rapid, highly accurate, and robust, direct-to-PCR technologies with the power to transform molecular testing for infectious
More news about: Transformative Biotech, LLC
Dec 10, 2025, 08:52 ET Dose-Intensive CK0804 Regimen Reduces Spleen Volume and Transfusion Needs in JAK Inhibitor-Resistant/ Suboptimal Myelofibrosis with Thrombocytopenia
intravenously through a peripheral line in an outpatient setting.About Cellenkos, Inc.Cellenkos, Inc. is a clinical‑stage biotechnology company developing allogeneic, off‑the‑shelf T regulatory (Treg) cell therapies for autoimmune and inflammatory diseases. Tregs are key immune cells
More news about: Cellenkos, Inc.
Dec 10, 2025, 08:37 ET Aramore Wins "Best Breakthrough Wellness Startup" in the 2025 Glossy Awards
www.aramore.com and select retail partners nationwide.About AramoreFounded at the intersection of biotechnology and beauty, Aramore is a pioneering skincare brand focused on longevity through cellular health. Backed by scientific research from MIT and Harvard,
More news about: ARAMORE Skincare
Dec 10, 2025, 08:00 ET Diakonos Oncology Awarded Multi-Million-Dollar Research Grant by the Cancer Prevention and Research Institute of Texas to Advance DOC1021 in Refractory Melanoma
Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced that the Company was selected
More news about: Diakonos Oncology